首页 > 最新文献

Medical review (Berlin, Germany)最新文献

英文 中文
Evidence-based rehabilitation medicine: definition, foundation, practice and development 循证康复医学:定义、基础、实践与发展
Pub Date : 2023-09-25 DOI: 10.1515/mr-2023-0027
Jinlong Zhang, Chengqi He
Abstract To determine the definition, foundation, practice, and development of evidence-based rehabilitation medicine (EBRM) and point out the development direction for EBRM. Retrieve the database of PubMed, Cochrane Library, Embase, China national knowledge infrastructure (CNKI), Wanfang, and China science and technology journal database (CSTJ). The search was conducted from the establishment of the database to June 2023. The key words are “rehabilitation medicine and evidence based” in Chinese and English. After reading the abstract or full text of the literature, a summary analysis is conducted to determine the definition, foundation, practice, and development of EBRM. A total of 127 articles were included. The development of 14 sub majors in EBRM are not balanced, evidence-based musculoskeletal rehabilitation medicine (EBMRM) (31 articles, mainly focuses on osteoarthritis, osteoporosis and musculoskeletal pain), evidence-based neurorehabilitation medicine (EBNM) (34 articles, mainly concentrated in stroke, traumatic brain injury and spinal cord injury) and evidence-based education rehabilitation medicine (EBEDRM) (17 articles, mainly focuses on educational methodology), evidence-based nursing rehabilitation medicine (EBNRM) (2 articles), evidence-based engineering rehabilitation medicine (EBENRM) (7 articles), evidence-based traditional Chinese rehabilitation medicine (EBTCRM) (3 articles), evidence-based internal rehabilitation medicine (EBIRM) (11 articles), evidence-based intensive care rehabilitation medicine (EBICRM) (4 articles), evidence-based oncology rehabilitation medicine (EBORM) (6 articles), evidence-based physical therapy medicine (EBPTM) (3 articles), evidence-based cardiopulmonary rehabilitation medicine (EBCRM) (6 articles), evidence-based speech therapy medicine (EBSTM)/evidence-based occupation therapy medicine (EBOTM)/evidence-based geriatric rehabilitation medicine (EBGRM) (1 article). The EBMRM, EBNM and EBEDRM are relatively well developed. The development of EBNRM, EBENRM, EBTCRM, EBIRM, EBICRM, EBGRM, EBORM, EBCRM, EBPTM, EBSTM and EBOTM is relatively slow, indicating these eleven fields should be pay more attention in future.
确定循证康复医学的定义、基础、实践和发展,指出循证康复医学的发展方向。检索PubMed、Cochrane Library、Embase、中国知网、万方、中国科技期刊库等数据库。检索时间为数据库建立至2023年6月。关键词是“康复医学”和“循证”。在阅读文献摘要或全文后,进行总结分析,确定EBRM的定义、基础、实践和发展。共纳入127条。循证肌肉骨骼康复医学(EBMRM)(31篇,主要集中在骨关节炎、骨质疏松症和肌肉骨骼疼痛)、循证神经康复医学(EBNM)(34篇,主要集中在中风、创伤性脑损伤和脊髓损伤)和循证教育康复医学(EBEDRM)(17篇,主要集中在教育方法论)等14个子专业发展不均衡。循证护理康复医学(EBNRM)(2篇)、循证工程康复医学(EBENRM)(7篇)、循证中医康复医学(EBTCRM)(3篇)、循证内科康复医学(EBIRM)(11篇)、循证重症康复医学(EBICRM)(4篇)、循证肿瘤康复医学(EBORM)(6篇)、循证物理治疗医学(EBPTM)(3篇)、循证心肺康复医学(EBCRM)(6篇)、循证语言治疗医学(EBSTM)/循证职业治疗医学(EBOTM)/循证老年康复医学(EBGRM)(1篇)。EBMRM、EBNM和EBEDRM相对较发达。EBNRM、EBENRM、EBTCRM、EBIRM、EBICRM、EBGRM、EBORM、EBCRM、EBPTM、EBSTM和EBOTM的发展相对缓慢,这11个领域在未来应该得到更多的关注。
{"title":"Evidence-based rehabilitation medicine: definition, foundation, practice and development","authors":"Jinlong Zhang, Chengqi He","doi":"10.1515/mr-2023-0027","DOIUrl":"https://doi.org/10.1515/mr-2023-0027","url":null,"abstract":"Abstract To determine the definition, foundation, practice, and development of evidence-based rehabilitation medicine (EBRM) and point out the development direction for EBRM. Retrieve the database of PubMed, Cochrane Library, Embase, China national knowledge infrastructure (CNKI), Wanfang, and China science and technology journal database (CSTJ). The search was conducted from the establishment of the database to June 2023. The key words are “rehabilitation medicine and evidence based” in Chinese and English. After reading the abstract or full text of the literature, a summary analysis is conducted to determine the definition, foundation, practice, and development of EBRM. A total of 127 articles were included. The development of 14 sub majors in EBRM are not balanced, evidence-based musculoskeletal rehabilitation medicine (EBMRM) (31 articles, mainly focuses on osteoarthritis, osteoporosis and musculoskeletal pain), evidence-based neurorehabilitation medicine (EBNM) (34 articles, mainly concentrated in stroke, traumatic brain injury and spinal cord injury) and evidence-based education rehabilitation medicine (EBEDRM) (17 articles, mainly focuses on educational methodology), evidence-based nursing rehabilitation medicine (EBNRM) (2 articles), evidence-based engineering rehabilitation medicine (EBENRM) (7 articles), evidence-based traditional Chinese rehabilitation medicine (EBTCRM) (3 articles), evidence-based internal rehabilitation medicine (EBIRM) (11 articles), evidence-based intensive care rehabilitation medicine (EBICRM) (4 articles), evidence-based oncology rehabilitation medicine (EBORM) (6 articles), evidence-based physical therapy medicine (EBPTM) (3 articles), evidence-based cardiopulmonary rehabilitation medicine (EBCRM) (6 articles), evidence-based speech therapy medicine (EBSTM)/evidence-based occupation therapy medicine (EBOTM)/evidence-based geriatric rehabilitation medicine (EBGRM) (1 article). The EBMRM, EBNM and EBEDRM are relatively well developed. The development of EBNRM, EBENRM, EBTCRM, EBIRM, EBICRM, EBGRM, EBORM, EBCRM, EBPTM, EBSTM and EBOTM is relatively slow, indicating these eleven fields should be pay more attention in future.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135769830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The mTOR pathway in the antiphospholipid syndrome 抗磷脂综合征的mTOR通路
Pub Date : 2023-09-21 DOI: 10.1515/mr-2023-0033
Lanlan Ji, Zhuoli Zhang, Andras Perl
Abstract This perspective discussed the available evidence on the involvement of mTOR pathway in antiphospholipid syndrome (APS), from the aspects of endothelial cells, platelets, monocytes and anti-phospholipid antibodies (PLs), which may lead to future therapeutic applications of mTOR inhibition in APS.
本文从内皮细胞、血小板、单核细胞和抗磷脂抗体等方面探讨了mTOR通路参与抗磷脂综合征(APS)的现有证据,为mTOR抑制在APS中的治疗应用提供参考。
{"title":"The mTOR pathway in the antiphospholipid syndrome","authors":"Lanlan Ji, Zhuoli Zhang, Andras Perl","doi":"10.1515/mr-2023-0033","DOIUrl":"https://doi.org/10.1515/mr-2023-0033","url":null,"abstract":"Abstract This perspective discussed the available evidence on the involvement of mTOR pathway in antiphospholipid syndrome (APS), from the aspects of endothelial cells, platelets, monocytes and anti-phospholipid antibodies (PLs), which may lead to future therapeutic applications of mTOR inhibition in APS.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron oxide nanoparticles in magnetic drug targeting and ferroptosis-based cancer therapy 氧化铁纳米颗粒在磁性药物靶向和基于铁中毒的癌症治疗中的应用
Pub Date : 2023-09-20 DOI: 10.1515/mr-2023-0029
Quazi T. H. Shubhra
Abstract Iron oxide (IO) nanoparticles (NPs) have gained significant attention in the field of biomedicine, particularly in drug targeting and cancer therapy. Their potential in magnetic drug targeting (MDT) and ferroptosis-based cancer therapy is highly promising. IO NPs serve as an effective drug delivery system (DDS), utilizing external magnetic fields (EMFs) to target cancer cells while minimizing damage to healthy organs. Additionally, IO NPs can generate reactive oxygen species (ROS) and induce ferroptosis, resulting in cytotoxic effects on cancer cells. This article explores how IO NPs can potentially revolutionize cancer research, focusing on their applications in MDT and ferroptosis-based therapy.
摘要氧化铁纳米颗粒(Iron oxide nanoparticles, NPs)在生物医学领域,特别是在药物靶向治疗和癌症治疗方面受到了广泛的关注。它们在磁性药物靶向(MDT)和基于铁中毒的癌症治疗方面具有很大的潜力。IO NPs作为一种有效的药物递送系统(DDS),利用外部磁场(emf)靶向癌细胞,同时最大限度地减少对健康器官的损害。此外,IO NPs可以产生活性氧(ROS),诱导铁下垂,对癌细胞产生细胞毒性作用。本文探讨了IO NPs如何可能彻底改变癌症研究,重点介绍了它们在MDT和基于铁细胞凋亡的治疗中的应用。
{"title":"Iron oxide nanoparticles in magnetic drug targeting and ferroptosis-based cancer therapy","authors":"Quazi T. H. Shubhra","doi":"10.1515/mr-2023-0029","DOIUrl":"https://doi.org/10.1515/mr-2023-0029","url":null,"abstract":"Abstract Iron oxide (IO) nanoparticles (NPs) have gained significant attention in the field of biomedicine, particularly in drug targeting and cancer therapy. Their potential in magnetic drug targeting (MDT) and ferroptosis-based cancer therapy is highly promising. IO NPs serve as an effective drug delivery system (DDS), utilizing external magnetic fields (EMFs) to target cancer cells while minimizing damage to healthy organs. Additionally, IO NPs can generate reactive oxygen species (ROS) and induce ferroptosis, resulting in cytotoxic effects on cancer cells. This article explores how IO NPs can potentially revolutionize cancer research, focusing on their applications in MDT and ferroptosis-based therapy.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136263676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Enrichment of nano delivery platforms for mRNA-based nanotherapeutics 基于mrna的纳米治疗药物纳米递送平台的富集
Pub Date : 2023-09-20 DOI: 10.1515/mr-2023-0010
Xiao Liu, Xu Zhang, Jiulong Li, Huan Meng
Abstract Lipid-based nanoparticles (LNP) have shown significant progress in delivering mRNA for therapeutics, particularly with the success of coronavirus disease 2019 (COVID-19) vaccines. However, there are still challenges, such as organ-specific targeting, sustained protein expression, immunogenicity, and storage that need to be addressed. Therefore, there is interest in developing additional nano drug delivery systems (DDS) to complement LNP technology. Some of these include polymer, lipid-polymer hybrid, organic/inorganic hybrid nanostructure, and inorganic nanoparticle. In our opinion, LNP technology may not be suitable for every disease scenario in categories such as infection disease, cancer, pulmonary disease, autoimmune disorders and genetic rare disease (among others). This is because different diseases may require distinct administration routes, doses, and treatment durations, as well as considerations for biological barriers that may lower the efficacy and/or exert safety concern. In this perspective, we will highlight the need and potential for enhancing the diversity of nano delivery platforms for mRNA-based nanotherapeutics.
基于脂质的纳米颗粒(LNP)在递送mRNA用于治疗方面取得了重大进展,特别是随着2019冠状病毒病(COVID-19)疫苗的成功。然而,仍然存在需要解决的挑战,如器官特异性靶向,持续蛋白表达,免疫原性和储存。因此,有兴趣开发额外的纳米药物递送系统(DDS)来补充LNP技术。其中包括聚合物、脂质-聚合物杂化、有机/无机杂化纳米结构和无机纳米颗粒。我们认为,LNP技术可能并不适用于感染性疾病、癌症、肺部疾病、自身免疫性疾病和遗传性罕见病等类别的所有疾病场景。这是因为不同的疾病可能需要不同的给药途径、剂量和治疗持续时间,以及考虑可能降低疗效和/或产生安全性问题的生物屏障。从这个角度来看,我们将强调增强基于mrna的纳米治疗药物的纳米递送平台多样性的需求和潜力。
{"title":"Enrichment of nano delivery platforms for mRNA-based nanotherapeutics","authors":"Xiao Liu, Xu Zhang, Jiulong Li, Huan Meng","doi":"10.1515/mr-2023-0010","DOIUrl":"https://doi.org/10.1515/mr-2023-0010","url":null,"abstract":"Abstract Lipid-based nanoparticles (LNP) have shown significant progress in delivering mRNA for therapeutics, particularly with the success of coronavirus disease 2019 (COVID-19) vaccines. However, there are still challenges, such as organ-specific targeting, sustained protein expression, immunogenicity, and storage that need to be addressed. Therefore, there is interest in developing additional nano drug delivery systems (DDS) to complement LNP technology. Some of these include polymer, lipid-polymer hybrid, organic/inorganic hybrid nanostructure, and inorganic nanoparticle. In our opinion, LNP technology may not be suitable for every disease scenario in categories such as infection disease, cancer, pulmonary disease, autoimmune disorders and genetic rare disease (among others). This is because different diseases may require distinct administration routes, doses, and treatment durations, as well as considerations for biological barriers that may lower the efficacy and/or exert safety concern. In this perspective, we will highlight the need and potential for enhancing the diversity of nano delivery platforms for mRNA-based nanotherapeutics.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136263565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities 用于癌症治疗的智能纳米材料:最新进展和未来的可能性
Pub Date : 2023-09-20 DOI: 10.1515/mr-2023-0028
Jing Wang, Yuliang Zhao, Guangjun Nie
Abstract Intelligent nanomedicine is currently one of the most active frontiers in cancer therapy development. Empowered by the recent progresses of nanobiotechnology, a new generation of multifunctional nanotherapeutics and imaging platforms has remarkably improved our capability to cope with the highly heterogeneous and complicated nature of cancer. With rationally designed multifunctionality and programmable assembly of functional subunits, the in vivo behaviors of intelligent nanosystems have become increasingly tunable, making them more efficient in performing sophisticated actions in physiological and pathological microenvironments. In recent years, intelligent nanomaterial-based theranostic platforms have showed great potential in tumor-targeted delivery, biological barrier circumvention, multi-responsive tumor sensing and drug release, as well as convergence with precise medication approaches such as personalized tumor vaccines. On the other hand, the increasing system complexity of anti-cancer nanomedicines also pose significant challenges in characterization, monitoring and clinical use, requesting a more comprehensive and dynamic understanding of nano-bio interactions. This review aims to briefly summarize the recent progresses achieved by intelligent nanomaterials in tumor-targeted drug delivery, tumor immunotherapy and temporospatially specific tumor imaging, as well as important advances of our knowledge on their interaction with biological systems. In the perspective of clinical translation, we have further discussed the major possibilities provided by disease-oriented development of anti-cancer nanomaterials, highlighting the critical importance clinically-oriented system design.
摘要智能纳米医学是目前肿瘤治疗发展最活跃的前沿之一。随着纳米生物技术的发展,新一代多功能纳米疗法和成像平台显著提高了我们应对癌症高度异质性和复杂性的能力。通过合理设计功能亚基的多功能性和可编程组装,智能纳米系统的体内行为变得越来越可调,使其在生理和病理微环境中更有效地执行复杂的动作。近年来,基于纳米材料的智能治疗平台在肿瘤靶向递送、生物屏障规避、多响应肿瘤传感和药物释放以及与个性化肿瘤疫苗等精准用药途径的融合等方面显示出巨大的潜力。另一方面,抗癌纳米药物系统复杂性的增加也给表征、监测和临床应用带来了重大挑战,要求对纳米生物相互作用有更全面和动态的了解。本文综述了智能纳米材料在肿瘤靶向药物递送、肿瘤免疫治疗和肿瘤时空特异性成像等方面的最新进展,以及它们与生物系统相互作用方面的重要进展。从临床转化的角度,我们进一步讨论了以疾病为导向的抗癌纳米材料开发提供的主要可能性,强调了以临床为导向的系统设计的重要性。
{"title":"Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities","authors":"Jing Wang, Yuliang Zhao, Guangjun Nie","doi":"10.1515/mr-2023-0028","DOIUrl":"https://doi.org/10.1515/mr-2023-0028","url":null,"abstract":"Abstract Intelligent nanomedicine is currently one of the most active frontiers in cancer therapy development. Empowered by the recent progresses of nanobiotechnology, a new generation of multifunctional nanotherapeutics and imaging platforms has remarkably improved our capability to cope with the highly heterogeneous and complicated nature of cancer. With rationally designed multifunctionality and programmable assembly of functional subunits, the in vivo behaviors of intelligent nanosystems have become increasingly tunable, making them more efficient in performing sophisticated actions in physiological and pathological microenvironments. In recent years, intelligent nanomaterial-based theranostic platforms have showed great potential in tumor-targeted delivery, biological barrier circumvention, multi-responsive tumor sensing and drug release, as well as convergence with precise medication approaches such as personalized tumor vaccines. On the other hand, the increasing system complexity of anti-cancer nanomedicines also pose significant challenges in characterization, monitoring and clinical use, requesting a more comprehensive and dynamic understanding of nano-bio interactions. This review aims to briefly summarize the recent progresses achieved by intelligent nanomaterials in tumor-targeted drug delivery, tumor immunotherapy and temporospatially specific tumor imaging, as well as important advances of our knowledge on their interaction with biological systems. In the perspective of clinical translation, we have further discussed the major possibilities provided by disease-oriented development of anti-cancer nanomaterials, highlighting the critical importance clinically-oriented system design.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136263563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanostructured boron agents for boron neutron capture therapy: a review of recent patents 用于硼中子俘获治疗的纳米结构硼剂:近期专利综述
Pub Date : 2023-09-15 DOI: 10.1515/mr-2023-0013
Xiyin Zhang, Yusheng Lin, Narayan S. Hosmane, Yinghuai Zhu
Abstract Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 ( 10 B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro- closo -dodecaborate (BSH) and boronophenylalanine (BPA), are mainly used in BNCT. Although both have suboptimal tumor selectivity, they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors. To improve the efficacy of BNCT, great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles. This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people’s interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.
硼中子俘获治疗(BNCT)是一种潜在的癌症放射治疗方式,肿瘤靶向的稳定硼-10 (10b)递送剂是BNCT的重要组成部分。目前,两种低分子量的含硼化合物,巯基十氢-近十二硼酸钠(BSH)和硼苯丙氨酸(BPA),主要用于BNCT。尽管这两种方法的肿瘤选择性都不理想,但它们在高级别胶质瘤和其他几种肿瘤患者中显示出一些治疗效果。为了提高硼化硼的疗效,人们一直致力于开发新的硼递送剂,使其具有更好的吸收率和良好的药代动力学特征。本文综述了硼纳米材料作为硼载体在硼中子俘获治疗中的应用和研究进展,并希望通过总结近十年来公开的各类硼纳米材料专利,激发人们对纳米材料基递送剂的兴趣。
{"title":"Nanostructured boron agents for boron neutron capture therapy: a review of recent patents","authors":"Xiyin Zhang, Yusheng Lin, Narayan S. Hosmane, Yinghuai Zhu","doi":"10.1515/mr-2023-0013","DOIUrl":"https://doi.org/10.1515/mr-2023-0013","url":null,"abstract":"Abstract Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 ( 10 B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro- closo -dodecaborate (BSH) and boronophenylalanine (BPA), are mainly used in BNCT. Although both have suboptimal tumor selectivity, they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors. To improve the efficacy of BNCT, great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles. This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people’s interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135353087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lipid-based nanoparticles for cancer immunotherapy. 用于癌症免疫疗法的脂质基纳米粒子。
Pub Date : 2023-08-17 eCollection Date: 2023-06-01 DOI: 10.1515/mr-2023-0020
Shumin Fan, Huize Han, Zhicheng Yan, Yao Lu, Bing He, Qiang Zhang

As the fourth most important cancer management strategy except surgery, chemotherapy and radiotherapy, cancer immunotherapy has been confirmed to elicit durable antitumor effects in the clinic by leveraging the patient's own immune system to eradicate the cancer cells. However, the limited population of patients who benefit from the current immunotherapies and the immune related adverse events hinder its development. The immunosuppressive microenvironment is the main cause of the failure, which leads to cancer immune evasion and immunity cycle blockade. Encouragingly, nanotechnology has been engineered to enhance the efficacy and reduce off-target toxicity of their therapeutic cargos by spatiotemporally controlling the biodistribution and release kinetics. Among them, lipid-based nanoparticles are the first nanomedicines to make clinical translation, which are now established platforms for diverse areas. In this perspective, we discuss the available lipid-based nanoparticles in research and market here, then describe their application in cancer immunotherapy, with special emphasis on the T cells-activated and macrophages-targeted delivery system. Through perpetuating each step of cancer immunity cycle, lipid-based nanoparticles can reduce immunosuppression and promote drug delivery to trigger robust antitumor response.

作为除手术、化疗和放疗之外的第四种最重要的癌症管理策略,癌症免疫疗法已被证实通过利用患者自身的免疫系统根除癌症细胞,在临床上引发持久的抗肿瘤效果。然而,受益于当前免疫疗法和免疫相关不良事件的患者人数有限,阻碍了其发展。免疫抑制微环境是导致癌症免疫逃避和免疫循环阻断的主要原因。令人鼓舞的是,纳米技术已被设计为通过时空控制生物分布和释放动力学来提高其治疗货物的疗效并降低脱靶毒性。其中,基于脂质的纳米颗粒是第一批进行临床翻译的纳米药物,目前已为不同领域建立了平台。从这个角度来看,我们讨论了研究和市场上可用的基于脂质的纳米颗粒,然后描述了它们在癌症免疫疗法中的应用,特别强调了T细胞活化和巨噬细胞靶向递送系统。通过维持癌症免疫循环的每一步,基于脂质的纳米颗粒可以减少免疫抑制并促进药物递送,从而引发强大的抗肿瘤反应。
{"title":"Lipid-based nanoparticles for cancer immunotherapy.","authors":"Shumin Fan, Huize Han, Zhicheng Yan, Yao Lu, Bing He, Qiang Zhang","doi":"10.1515/mr-2023-0020","DOIUrl":"10.1515/mr-2023-0020","url":null,"abstract":"<p><p>As the fourth most important cancer management strategy except surgery, chemotherapy and radiotherapy, cancer immunotherapy has been confirmed to elicit durable antitumor effects in the clinic by leveraging the patient's own immune system to eradicate the cancer cells. However, the limited population of patients who benefit from the current immunotherapies and the immune related adverse events hinder its development. The immunosuppressive microenvironment is the main cause of the failure, which leads to cancer immune evasion and immunity cycle blockade. Encouragingly, nanotechnology has been engineered to enhance the efficacy and reduce off-target toxicity of their therapeutic cargos by spatiotemporally controlling the biodistribution and release kinetics. Among them, lipid-based nanoparticles are the first nanomedicines to make clinical translation, which are now established platforms for diverse areas. In this perspective, we discuss the available lipid-based nanoparticles in research and market here, then describe their application in cancer immunotherapy, with special emphasis on the T cells-activated and macrophages-targeted delivery system. Through perpetuating each step of cancer immunity cycle, lipid-based nanoparticles can reduce immunosuppression and promote drug delivery to trigger robust antitumor response.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"230-269"},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/54/mr-3-3-mr-2023-0020.PMC10542882.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in theranostics of gastric cancer, a review. 人工智能在癌症治疗中的应用综述。
Pub Date : 2023-07-27 eCollection Date: 2023-06-01 DOI: 10.1515/mr-2022-0042
Yiqian Zha, Cuili Xue, Yanlei Liu, Jian Ni, Jesus M De La Fuente, Daxiang Cui

Gastric cancer (GC) is one of the commonest cancers with high morbidity and mortality in the world. How to realize precise diagnosis and therapy of GC owns great clinical requirement. In recent years, artificial intelligence (AI) has been actively explored to apply to early diagnosis and treatment and prognosis of gastric carcinoma. Herein, we review recent advance of AI in early screening, diagnosis, therapy and prognosis of stomach carcinoma. Especially AI combined with breath screening early GC system improved 97.4 % of early GC diagnosis ratio, AI model on stomach cancer diagnosis system of saliva biomarkers obtained an overall accuracy of 97.18 %, specificity of 97.44 %, and sensitivity of 96.88 %. We also discuss concept, issues, approaches and challenges of AI applied in stomach cancer. This review provides a comprehensive view and roadmap for readers working in this field, with the aim of pushing application of AI in theranostics of stomach cancer to increase the early discovery ratio and curative ratio of GC patients.

癌症是世界上最常见的高发病率和高死亡率的癌症之一。如何实现GC的精确诊断和治疗对临床有很大的要求。近年来,人工智能(AI)被积极探索应用于胃癌的早期诊断、治疗和预后。在此,我们综述了人工智能在胃癌早期筛查、诊断、治疗和预后方面的最新进展。特别是AI结合呼吸筛查早期GC系统提高了97.4 % 在早期GC诊断率中,AI模型对癌症唾液生物标志物诊断系统的总体准确率为97.18 %, 特异性为97.44 %, 灵敏度为96.88 %. 我们还讨论了人工智能应用于癌症的概念、问题、方法和挑战。这篇综述为该领域的读者提供了一个全面的观点和路线图,目的是推动人工智能在癌症治疗中的应用,以提高GC患者的早期发现率和治愈率。
{"title":"Artificial intelligence in theranostics of gastric cancer, a review.","authors":"Yiqian Zha, Cuili Xue, Yanlei Liu, Jian Ni, Jesus M De La Fuente, Daxiang Cui","doi":"10.1515/mr-2022-0042","DOIUrl":"10.1515/mr-2022-0042","url":null,"abstract":"<p><p>Gastric cancer (GC) is one of the commonest cancers with high morbidity and mortality in the world. How to realize precise diagnosis and therapy of GC owns great clinical requirement. In recent years, artificial intelligence (AI) has been actively explored to apply to early diagnosis and treatment and prognosis of gastric carcinoma. Herein, we review recent advance of AI in early screening, diagnosis, therapy and prognosis of stomach carcinoma. Especially AI combined with breath screening early GC system improved 97.4 % of early GC diagnosis ratio, AI model on stomach cancer diagnosis system of saliva biomarkers obtained an overall accuracy of 97.18 %, specificity of 97.44 %, and sensitivity of 96.88 %. We also discuss concept, issues, approaches and challenges of AI applied in stomach cancer. This review provides a comprehensive view and roadmap for readers working in this field, with the aim of pushing application of AI in theranostics of stomach cancer to increase the early discovery ratio and curative ratio of GC patients.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"214-229"},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/ce/mr-3-3-mr-2022-0042.PMC10542883.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of cutting-edge artificial intelligence technologies in biomedical literature and document mining. 前沿人工智能技术在生物医学文献和文献挖掘中的应用。
Pub Date : 2023-06-27 eCollection Date: 2023-06-01 DOI: 10.1515/mr-2023-0011
Fei He, Kai Liu, Zhiyuan Yang, Mark Hannink, Richard D Hammer, Mihail Popescu, Dong Xu

The biomedical literature is a vast and invaluable resource for biomedical research. Integrating knowledge from the literature with biomedical data can help biological studies and the clinical decision-making process. Efforts have been made to gather information from the biomedical literature and create biomedical knowledge bases, such as KEGG and Reactome. However, manual curation remains the primary method to retrieve accurate biomedical entities and relationships. Manual curation becomes increasingly challenging and costly as the volume of biomedical publications quickly grows. Fortunately, recent advancements in Artificial Intelligence (AI) technologies offer the potential to automate the process of curating, updating, and integrating knowledge from the literature. Herein, we highlight the AI capabilities to aid in mining knowledge and building the knowledge base from the biomedical literature.

生物医学文献是生物医学研究的宝贵资源。将文献中的知识与生物医学数据相结合可以帮助生物学研究和临床决策过程。已经努力从生物医学文献中收集信息,并创建生物医学知识库,如KEGG和Reactome。然而,手动管理仍然是检索准确的生物医学实体和关系的主要方法。随着生物医学出版物数量的快速增长,手工策展变得越来越具有挑战性,成本也越来越高。幸运的是,人工智能(AI)技术的最新进展提供了自动化管理、更新和整合文献知识过程的潜力。在此,我们强调了人工智能在帮助挖掘生物医学文献中的知识和建立知识库方面的能力。
{"title":"Applications of cutting-edge artificial intelligence technologies in biomedical literature and document mining.","authors":"Fei He, Kai Liu, Zhiyuan Yang, Mark Hannink, Richard D Hammer, Mihail Popescu, Dong Xu","doi":"10.1515/mr-2023-0011","DOIUrl":"10.1515/mr-2023-0011","url":null,"abstract":"<p><p>The biomedical literature is a vast and invaluable resource for biomedical research. Integrating knowledge from the literature with biomedical data can help biological studies and the clinical decision-making process. Efforts have been made to gather information from the biomedical literature and create biomedical knowledge bases, such as KEGG and Reactome. However, manual curation remains the primary method to retrieve accurate biomedical entities and relationships. Manual curation becomes increasingly challenging and costly as the volume of biomedical publications quickly grows. Fortunately, recent advancements in Artificial Intelligence (AI) technologies offer the potential to automate the process of curating, updating, and integrating knowledge from the literature. Herein, we highlight the AI capabilities to aid in mining knowledge and building the knowledge base from the biomedical literature.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"200-204"},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/25/mr-3-3-mr-2023-0011.PMC10542881.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral microbiome: a doubtful predictor but potential target of cardiovascular diseases. 口腔微生物组:一个值得怀疑的预测因素,但可能成为心血管疾病的靶点。
Pub Date : 2023-06-22 eCollection Date: 2023-06-01 DOI: 10.1515/mr-2023-0015
Chak Kwong Cheng, Yu Huang

Our oral cavity houses various types of microbes including bacteria, protozoa, fungi and viruses, harboring over 700 bacterial species. Oral dysbiosis refers to the imbalance between symbionts and pathobionts in the oral cavity, posing potential threats to host cardiovascular health. Importantly, oral dysbiosis promotes cardiovascular pathophysiology through different mechanisms. Although overgrowth of certain pathogenic bacteria have been indicated in some cardiometabolic diseases, it is still premature to consider oral microbiome as a suitable predictor for non-invasive diagnostic purpose. However, targeting oral microbiome might still provide preventive and therapeutic insights on cardiovascular diseases. Further extensive efforts are needed to deepen our understanding on oral-cardiovascular connection in the context of diagnostic and therapeutic perspectives.

我们的口腔中有各种类型的微生物,包括细菌、原生动物、真菌和病毒,共有700多种细菌。口腔微生态失调是指口腔中共生体和病理生物之间的失衡,对宿主的心血管健康构成潜在威胁。重要的是,口腔微生态失调通过不同的机制促进心血管病理生理学。尽管某些心脏代谢疾病中已表明某些致病菌过度生长,但将口腔微生物组视为非侵入性诊断目的的合适预测因素还为时过早。然而,靶向口腔微生物组仍然可能为心血管疾病的预防和治疗提供见解。需要进一步广泛的努力,从诊断和治疗的角度加深我们对口腔心血管联系的理解。
{"title":"Oral microbiome: a doubtful predictor but potential target of cardiovascular diseases.","authors":"Chak Kwong Cheng, Yu Huang","doi":"10.1515/mr-2023-0015","DOIUrl":"10.1515/mr-2023-0015","url":null,"abstract":"<p><p>Our oral cavity houses various types of microbes including bacteria, protozoa, fungi and viruses, harboring over 700 bacterial species. Oral dysbiosis refers to the imbalance between symbionts and pathobionts in the oral cavity, posing potential threats to host cardiovascular health. Importantly, oral dysbiosis promotes cardiovascular pathophysiology through different mechanisms. Although overgrowth of certain pathogenic bacteria have been indicated in some cardiometabolic diseases, it is still premature to consider oral microbiome as a suitable predictor for non-invasive diagnostic purpose. However, targeting oral microbiome might still provide preventive and therapeutic insights on cardiovascular diseases. Further extensive efforts are needed to deepen our understanding on oral-cardiovascular connection in the context of diagnostic and therapeutic perspectives.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"209-213"},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/bd/mr-3-3-mr-2023-0015.PMC10542880.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical review (Berlin, Germany)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1